View Past PerformanceThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsOrapi 대차대조표 건전성재무 건전성 기준 점검 5/6Orapi 의 총 주주 지분은 €28.9M 이고 총 부채는 €40.2M, 이는 부채 대 자기자본 비율을 139.2% 로 가져옵니다. 총자산과 총부채는 각각 €179.3M 및 €150.4M 입니다.핵심 정보139.17%부채/자본 비율€40.20m부채이자보상배율n/a현금€11.94m자본€28.89m총부채€150.37m총자산€179.26m최근 재무 건전성 업데이트분석 기사 • May 20Is Orapi (EPA:ORAP) A Risky Investment?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...분석 기사 • Nov 17Orapi (EPA:ORAP) Has A Somewhat Strained Balance SheetThe external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...분석 기사 • Apr 19Is Orapi (EPA:ORAP) A Risky Investment?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...분석 기사 • Dec 15We Think Orapi (EPA:ORAP) Is Taking Some Risk With Its DebtDavid Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...모든 업데이트 보기Recent updatesNew Risk • Dec 03New major risk - Revenue and earnings growthEarnings have declined by 76% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 76% per year over the past 5 years. Minor Risk Market cap is less than US$100m (€42.3m market cap, or US$44.6m).New Risk • Nov 01New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next year. Trailing 12-month net loss: €27m Forecast net loss in 1 year: €6.5m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable next year (€6.5m net loss next year). Market cap is less than US$100m (€42.1m market cap, or US$45.6m).Price Target Changed • Sep 11Price target increased by 8.3% to €6.50Up from €6.00, the current price target is provided by 1 analyst. New target price is approximately in line with last closing price of €6.40. The company is forecast to post a net loss per share of €2.11 next year compared to a net loss per share of €2.87 last year.New Risk • Jul 23New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of French stocks, typically moving 6.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (6.7% average weekly change). Market cap is less than US$100m (€41.4m market cap, or US$45.0m).Reported Earnings • Apr 19Full year 2023 earnings released: €2.89 loss per share (vs €0.12 profit in FY 2022)Full year 2023 results: €2.89 loss per share (down from €0.12 profit in FY 2022). Revenue: €229.1m (flat on FY 2022). Net loss: €18.8m (down €19.6m from profit in FY 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 140 percentage points per year, which is a significant difference in performance.New Risk • Apr 08New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Currently unprofitable and not forecast to become profitable next year (€8.8m net loss next year). Market cap is less than US$100m (€42.3m market cap, or US$45.9m).Reported Earnings • Sep 22First half 2023 earnings released: €0.89 loss per share (vs €0.34 profit in 1H 2022)First half 2023 results: €0.89 loss per share (down from €0.34 profit in 1H 2022). Revenue: €121.0m (up 1.6% from 1H 2022). Net loss: €5.82m (down 362% from profit in 1H 2022). Revenue is forecast to grow 4.4% p.a. on average during the next 2 years, compared to a 4.4% growth forecast for the Chemicals industry in France. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 112 percentage points per year, which is a significant difference in performance.New Risk • Aug 14New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of French stocks, typically moving 9.2% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (9.2% average weekly change). Minor Risks High level of debt (48% net debt to equity). Large one-off items impacting financial results. Market cap is less than US$100m (€41.7m market cap, or US$45.7m).분석 기사 • Aug 09Orapi (EPA:ORAP) Is Reinvesting At Lower Rates Of ReturnWhat trends should we look for it we want to identify stocks that can multiply in value over the long term? Typically...Valuation Update With 7 Day Price Move • Jun 28Investor sentiment improves as stock rises 24%After last week's 24% share price gain to €5.66, the stock trades at a forward P/E ratio of 10x. Average forward P/E is 11x in the Chemicals industry in France. Total loss to shareholders of 26% over the past three years.New Risk • Jun 15New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of French stocks, typically moving 6.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks High level of debt (48% net debt to equity). Share price has been volatile over the past 3 months (6.4% average weekly change). Large one-off items impacting financial results. Market cap is less than US$100m (€28.7m market cap, or US$31.1m).분석 기사 • Jun 13Investors Still Waiting For A Pull Back In Orapi SA (EPA:ORAP)When close to half the companies in France have price-to-earnings ratios (or "P/E's") below 14x, you may consider Orapi...Valuation Update With 7 Day Price Move • Jun 12Investor sentiment improves as stock rises 17%After last week's 17% share price gain to €4.57, the stock trades at a forward P/E ratio of 8x. Average forward P/E is 17x in the Chemicals industry in France. Total loss to shareholders of 44% over the past three years.Major Estimate Revision • May 11Consensus EPS estimates fall by 12%The consensus outlook for fiscal year 2023 has been updated. 2023 EPS estimate fell from €0.659 to €0.58. Revenue forecast unchanged from €241.1m at last update. Net income forecast to grow 376% next year vs 16% growth forecast for Chemicals industry in France. Consensus price target down from €8.50 to €7.10. Share price rose 2.1% to €3.88 over the past week.Price Target Changed • May 10Price target decreased by 14% to €7.10Down from €8.30, the current price target is provided by 1 analyst. New target price is 82% above last closing price of €3.91. Stock is down 24% over the past year. The company is forecast to post earnings per share of €0.66 for next year compared to €0.12 last year.분석 기사 • Mar 30Calculating The Fair Value Of Orapi SA (EPA:ORAP)Key Insights Using the 2 Stage Free Cash Flow to Equity, Orapi fair value estimate is €4.23 Orapi's €4.02 share price...분석 기사 • Nov 17A Look At The Fair Value Of Orapi SA (EPA:ORAP)Today we will run through one way of estimating the intrinsic value of Orapi SA ( EPA:ORAP ) by projecting its future...Price Target Changed • Nov 16Price target decreased to €8.30Down from €9.90, the current price target is provided by 1 analyst. New target price is 77% above last closing price of €4.68. Stock is down 30% over the past year. The company is forecast to post earnings per share of €0.26 for next year compared to €0.03 last year.Buying Opportunity • Oct 13Now 22% undervalued after recent price dropOver the last 90 days, the stock is down 18%. The fair value is estimated to be €5.24, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Meanwhile, the company has become profitable. For the next 3 years, revenue is forecast to grow by 3.8% per annum. Earnings is also forecast to grow by 54% per annum over the same time period.Major Estimate Revision • Sep 27Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 EPS estimate fell from €0.33 to €0.28. Revenue forecast unchanged from €234.8m at last update. Net income forecast to grow 1,153% next year vs 2.9% growth forecast for Chemicals industry in France. Consensus price target down from €10.80 to €9.90. Share price fell 2.4% to €4.49 over the past week.Price Target Changed • Sep 26Price target decreased to €9.90Down from €11.00, the current price target is provided by 1 analyst. New target price is 121% above last closing price of €4.48. Stock is down 34% over the past year. The company is forecast to post earnings per share of €0.33 for next year compared to €0.03 last year.Buying Opportunity • Sep 08Now 20% undervalued after recent price dropOver the last 90 days, the stock is down 6.9%. The fair value is estimated to be €5.89, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Meanwhile, the company has become profitable. For the next 3 years, revenue is forecast to grow by 3.8% per annum. Earnings is also forecast to grow by 52% per annum over the same time period.분석 기사 • Aug 22Orapi (EPA:ORAP) Might Have The Makings Of A Multi-BaggerThere are a few key trends to look for if we want to identify the next multi-bagger. Firstly, we'll want to see a...분석 기사 • Jun 30Calculating The Fair Value Of Orapi SA (EPA:ORAP)How far off is Orapi SA ( EPA:ORAP ) from its intrinsic value? Using the most recent financial data, we'll take a look...Buying Opportunity • Jun 10Now 22% undervaluedThe stock has been flat over the last 90 days. The fair value is estimated to be €6.45, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Meanwhile, the company has become profitable. Revenue is forecast to grow by 8.8% in 2 years. Earnings is forecast to grow by 2,059% in the next 2 years.분석 기사 • May 20Is Orapi (EPA:ORAP) A Risky Investment?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Buying Opportunity • May 12Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 15%. The fair value is estimated to be €6.37, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Meanwhile, the company has become profitable. Revenue is forecast to grow by 8.8% in 2 years. Earnings is forecast to grow by 2,059% in the next 2 years.Major Estimate Revision • Apr 27Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 EPS estimate fell from €0.37 to €0.33. Revenue forecast unchanged from €237.0m at last update. Net income forecast to grow 1,397% next year vs 20% growth forecast for Chemicals industry in France. Consensus price target of €11.00 unchanged from last update. Share price fell 8.5% to €5.14 over the past week.Reported Earnings • Apr 16Full year 2021 earnings: EPS misses analyst expectationsFull year 2021 results: EPS: €0.03 (down from €1.70 in FY 2020). Revenue: €226.6m (down 15% from FY 2020). Net income: €195.0k (down 98% from FY 2020). Profit margin: 0.1% (down from 3.4% in FY 2020). The decrease in margin was driven by lower revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 100%. Over the next year, revenue is forecast to grow 4.6%, compared to a 22% growth forecast for the industry in France. Over the last 3 years on average, earnings per share has increased by 60% per year but the company’s share price has only increased by 2% per year, which means it is significantly lagging earnings growth.Major Estimate Revision • Mar 22Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 EPS estimate increased from €0.25 to €0.33. Revenue forecast unchanged at €237.0m. Net income forecast to shrink 61% next year vs 15% decline forecast for Chemicals industry in France. Consensus price target up from €10.02 to €10.50. Share price rose 6.2% to €5.84 over the past week.분석 기사 • Mar 15Returns At Orapi (EPA:ORAP) Are On The Way UpWhat trends should we look for it we want to identify stocks that can multiply in value over the long term? In a...Valuation Update With 7 Day Price Move • Mar 14Investor sentiment improved over the past weekAfter last week's 17% share price gain to €5.50, the stock trades at a forward P/E ratio of 43x. Average forward P/E is 13x in the Chemicals industry in France. Total loss to shareholders of 8.3% over the past three years.Price Target Changed • Feb 02Price target decreased to €10.50Down from €12.00, the current price target is provided by 1 analyst. New target price is 80% above last closing price of €5.84. Stock is down 41% over the past year. The company is forecast to post earnings per share of €0.0079 for next year compared to €1.70 last year.Valuation Update With 7 Day Price Move • Nov 29Investor sentiment improved over the past weekAfter last week's 17% share price gain to €7.50, the stock trades at a forward P/E ratio of 67x. Average forward P/E is 18x in the Chemicals industry in France. Total returns to shareholders of 23% over the past three years.분석 기사 • Nov 17Orapi (EPA:ORAP) Has A Somewhat Strained Balance SheetThe external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Reported Earnings • Sep 22First half 2021 earnings released: EPS €0.37 (vs €1.92 in 1H 2020)The company reported a poor first half result with weaker earnings, revenues and profit margins. First half 2021 results: Revenue: €117.6m (down 16% from 1H 2020). Net income: €2.46m (down 72% from 1H 2020). Profit margin: 2.1% (down from 6.3% in 1H 2020). Over the last 3 years on average, earnings per share has increased by 97% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings.Price Target Changed • Sep 21Price target increased to €12.00Up from €10.50, the current price target is provided by 1 analyst. New target price is 73% above last closing price of €6.92. Stock is up 21% over the past year.Price Target Changed • Jul 27Price target decreased to €10.50Down from €11.60, the current price target is provided by 1 analyst. New target price is 56% above last closing price of €6.72. Stock is up 5.0% over the past year.Major Estimate Revision • Jul 27Consensus EPS estimates fall to €0.075The consensus outlook for earnings per share (EPS) in 2021 has deteriorated. 2021 revenue forecast decreased from €240.0m to €233.0m. EPS estimate also fell from €0.096 to €0.075. Net income forecast to shrink 87% next year vs 12% growth forecast for Chemicals industry in France . Consensus price target down from €11.60 to €10.50. Share price was steady at €6.72 over the past week.Major Estimate Revision • Jul 06Consensus forecasts updatedThe consensus outlook for 2021 has been updated. 2021 EPS estimate increased from €0.059 to €0.096. Revenue forecast unchanged at €240.0m. Net income forecast to shrink 83% next year vs 12% growth forecast for Chemicals industry in France . Consensus price target of €11.60 unchanged from last update. Share price rose 2.2% to €6.98 over the past week.분석 기사 • Apr 25Orapi's (EPA:ORAP) Earnings Are Of Questionable QualityDespite posting some strong earnings, the market for Orapi SA's ( EPA:ORAP ) stock hasn't moved much. Our analysis...분석 기사 • Apr 19Is Orapi (EPA:ORAP) A Risky Investment?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Reported Earnings • Apr 17Full year 2020 earnings released: EPS €1.70 (vs €0.64 loss in FY 2019)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: €267.5m (up 11% from FY 2019). Net income: €9.22m (up €12.2m from FY 2019). Profit margin: 3.4% (up from net loss in FY 2019). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 94% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings.분석 기사 • Feb 23Does Orapi (EPA:ORAP) Have The DNA Of A Multi-Bagger?If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. One common...Is New 90 Day High Low • Jan 26New 90-day high: €11.30The company is up 69% from its price of €6.68 on 28 October 2020. The French market is up 15% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 3.0% over the same period.분석 기사 • Jan 19Is Orapi SA's (EPA:ORAP) ROE Of 0.8% Concerning?While some investors are already well versed in financial metrics (hat tip), this article is for those who would like...Is New 90 Day High Low • Dec 23New 90-day high: €8.90The company is up 56% from its price of €5.70 on 24 September 2020. The French market is up 14% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is down 2.0% over the same period.분석 기사 • Dec 15We Think Orapi (EPA:ORAP) Is Taking Some Risk With Its DebtDavid Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Is New 90 Day High Low • Oct 21New 90-day high: €8.66The company is up 3.0% from its price of €8.42 on 23 July 2020. The French market is flat over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is down 5.0% over the same period.Major Estimate Revision • Sep 23Analysts increase EPS estimates to €0.46The 2020 consensus revenue estimate increased from €240.9m to €256.0m. The company is forecast to report a profit instead of a loss, with analysts raising their EPS forecasts from -€0.63 to €0.46 for the same period. The Chemicals industry in France is expected to see an average net income growth of 3.7% next year. The consensus price target increased from €7.00 to €8.30. Share price is up 10.0% to €5.72 over the past week.Reported Earnings • Sep 19First half earnings releasedOver the last 12 months the company has reported total profits of €189.0k, down 94% from the prior year. Total revenue was €251.8m over the last 12 months, largely unchanged from the prior year.Price Target Changed • Sep 19Price target raised to €8.30Up from €7.00, the current price target is provided by 1 analyst. The new target price is 32% above the current share price of €6.28. As of last close, the stock is up 26% over the past year.재무 상태 분석단기부채: ORAP 의 단기 자산 ( €101.6M )이 단기 부채( €94.9M ).장기 부채: ORAP의 단기 자산(€101.6M)이 장기 부채(€55.5M)를 초과합니다.부채/자본 비율 추이 및 분석부채 수준: ORAP 의 순부채 대 자기자본 비율( 97.8% )은 높음으로 간주됩니다.부채 감소: ORAP의 부채 대비 자본 비율은 지난 5년 동안 155.6%에서 139.2%로 감소했습니다.대차대조표현금 보유 기간 분석과거에 평균적으로 손실을 기록해 온 기업의 경우, 최소 1년 이상의 현금 보유 기간이 있는지 평가합니다.안정적인 현금 활주로: 수익성이 없는 ORAP 현재의 플러스 무료 현금 흐름 수준을 유지한다면 3년 이상 충분한 현금 활주로를 보유하고 있습니다.예측 현금 활주로: ORAP 은(는) 수익성이 없지만 잉여 현금 흐름이 긍정적이고 매년 23.5 %씩 성장하기 때문에 3년 이상 충분한 현금 활주로를 보유하고 있습니다.건전한 기업 찾아보기7D1Y7D1Y7D1YMaterials 산업의 건실한 기업.View Dividend기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2024/12/23 00:03종가2024/12/20 00:00수익2024/06/30연간 수익2023/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Orapi SA는 1명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Stephanie LefebvreGilbert Dupont
분석 기사 • May 20Is Orapi (EPA:ORAP) A Risky Investment?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
분석 기사 • Nov 17Orapi (EPA:ORAP) Has A Somewhat Strained Balance SheetThe external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
분석 기사 • Apr 19Is Orapi (EPA:ORAP) A Risky Investment?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
분석 기사 • Dec 15We Think Orapi (EPA:ORAP) Is Taking Some Risk With Its DebtDavid Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
New Risk • Dec 03New major risk - Revenue and earnings growthEarnings have declined by 76% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 76% per year over the past 5 years. Minor Risk Market cap is less than US$100m (€42.3m market cap, or US$44.6m).
New Risk • Nov 01New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next year. Trailing 12-month net loss: €27m Forecast net loss in 1 year: €6.5m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable next year (€6.5m net loss next year). Market cap is less than US$100m (€42.1m market cap, or US$45.6m).
Price Target Changed • Sep 11Price target increased by 8.3% to €6.50Up from €6.00, the current price target is provided by 1 analyst. New target price is approximately in line with last closing price of €6.40. The company is forecast to post a net loss per share of €2.11 next year compared to a net loss per share of €2.87 last year.
New Risk • Jul 23New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of French stocks, typically moving 6.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (6.7% average weekly change). Market cap is less than US$100m (€41.4m market cap, or US$45.0m).
Reported Earnings • Apr 19Full year 2023 earnings released: €2.89 loss per share (vs €0.12 profit in FY 2022)Full year 2023 results: €2.89 loss per share (down from €0.12 profit in FY 2022). Revenue: €229.1m (flat on FY 2022). Net loss: €18.8m (down €19.6m from profit in FY 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 140 percentage points per year, which is a significant difference in performance.
New Risk • Apr 08New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Currently unprofitable and not forecast to become profitable next year (€8.8m net loss next year). Market cap is less than US$100m (€42.3m market cap, or US$45.9m).
Reported Earnings • Sep 22First half 2023 earnings released: €0.89 loss per share (vs €0.34 profit in 1H 2022)First half 2023 results: €0.89 loss per share (down from €0.34 profit in 1H 2022). Revenue: €121.0m (up 1.6% from 1H 2022). Net loss: €5.82m (down 362% from profit in 1H 2022). Revenue is forecast to grow 4.4% p.a. on average during the next 2 years, compared to a 4.4% growth forecast for the Chemicals industry in France. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 112 percentage points per year, which is a significant difference in performance.
New Risk • Aug 14New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of French stocks, typically moving 9.2% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (9.2% average weekly change). Minor Risks High level of debt (48% net debt to equity). Large one-off items impacting financial results. Market cap is less than US$100m (€41.7m market cap, or US$45.7m).
분석 기사 • Aug 09Orapi (EPA:ORAP) Is Reinvesting At Lower Rates Of ReturnWhat trends should we look for it we want to identify stocks that can multiply in value over the long term? Typically...
Valuation Update With 7 Day Price Move • Jun 28Investor sentiment improves as stock rises 24%After last week's 24% share price gain to €5.66, the stock trades at a forward P/E ratio of 10x. Average forward P/E is 11x in the Chemicals industry in France. Total loss to shareholders of 26% over the past three years.
New Risk • Jun 15New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of French stocks, typically moving 6.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks High level of debt (48% net debt to equity). Share price has been volatile over the past 3 months (6.4% average weekly change). Large one-off items impacting financial results. Market cap is less than US$100m (€28.7m market cap, or US$31.1m).
분석 기사 • Jun 13Investors Still Waiting For A Pull Back In Orapi SA (EPA:ORAP)When close to half the companies in France have price-to-earnings ratios (or "P/E's") below 14x, you may consider Orapi...
Valuation Update With 7 Day Price Move • Jun 12Investor sentiment improves as stock rises 17%After last week's 17% share price gain to €4.57, the stock trades at a forward P/E ratio of 8x. Average forward P/E is 17x in the Chemicals industry in France. Total loss to shareholders of 44% over the past three years.
Major Estimate Revision • May 11Consensus EPS estimates fall by 12%The consensus outlook for fiscal year 2023 has been updated. 2023 EPS estimate fell from €0.659 to €0.58. Revenue forecast unchanged from €241.1m at last update. Net income forecast to grow 376% next year vs 16% growth forecast for Chemicals industry in France. Consensus price target down from €8.50 to €7.10. Share price rose 2.1% to €3.88 over the past week.
Price Target Changed • May 10Price target decreased by 14% to €7.10Down from €8.30, the current price target is provided by 1 analyst. New target price is 82% above last closing price of €3.91. Stock is down 24% over the past year. The company is forecast to post earnings per share of €0.66 for next year compared to €0.12 last year.
분석 기사 • Mar 30Calculating The Fair Value Of Orapi SA (EPA:ORAP)Key Insights Using the 2 Stage Free Cash Flow to Equity, Orapi fair value estimate is €4.23 Orapi's €4.02 share price...
분석 기사 • Nov 17A Look At The Fair Value Of Orapi SA (EPA:ORAP)Today we will run through one way of estimating the intrinsic value of Orapi SA ( EPA:ORAP ) by projecting its future...
Price Target Changed • Nov 16Price target decreased to €8.30Down from €9.90, the current price target is provided by 1 analyst. New target price is 77% above last closing price of €4.68. Stock is down 30% over the past year. The company is forecast to post earnings per share of €0.26 for next year compared to €0.03 last year.
Buying Opportunity • Oct 13Now 22% undervalued after recent price dropOver the last 90 days, the stock is down 18%. The fair value is estimated to be €5.24, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Meanwhile, the company has become profitable. For the next 3 years, revenue is forecast to grow by 3.8% per annum. Earnings is also forecast to grow by 54% per annum over the same time period.
Major Estimate Revision • Sep 27Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 EPS estimate fell from €0.33 to €0.28. Revenue forecast unchanged from €234.8m at last update. Net income forecast to grow 1,153% next year vs 2.9% growth forecast for Chemicals industry in France. Consensus price target down from €10.80 to €9.90. Share price fell 2.4% to €4.49 over the past week.
Price Target Changed • Sep 26Price target decreased to €9.90Down from €11.00, the current price target is provided by 1 analyst. New target price is 121% above last closing price of €4.48. Stock is down 34% over the past year. The company is forecast to post earnings per share of €0.33 for next year compared to €0.03 last year.
Buying Opportunity • Sep 08Now 20% undervalued after recent price dropOver the last 90 days, the stock is down 6.9%. The fair value is estimated to be €5.89, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Meanwhile, the company has become profitable. For the next 3 years, revenue is forecast to grow by 3.8% per annum. Earnings is also forecast to grow by 52% per annum over the same time period.
분석 기사 • Aug 22Orapi (EPA:ORAP) Might Have The Makings Of A Multi-BaggerThere are a few key trends to look for if we want to identify the next multi-bagger. Firstly, we'll want to see a...
분석 기사 • Jun 30Calculating The Fair Value Of Orapi SA (EPA:ORAP)How far off is Orapi SA ( EPA:ORAP ) from its intrinsic value? Using the most recent financial data, we'll take a look...
Buying Opportunity • Jun 10Now 22% undervaluedThe stock has been flat over the last 90 days. The fair value is estimated to be €6.45, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Meanwhile, the company has become profitable. Revenue is forecast to grow by 8.8% in 2 years. Earnings is forecast to grow by 2,059% in the next 2 years.
분석 기사 • May 20Is Orapi (EPA:ORAP) A Risky Investment?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Buying Opportunity • May 12Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 15%. The fair value is estimated to be €6.37, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Meanwhile, the company has become profitable. Revenue is forecast to grow by 8.8% in 2 years. Earnings is forecast to grow by 2,059% in the next 2 years.
Major Estimate Revision • Apr 27Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 EPS estimate fell from €0.37 to €0.33. Revenue forecast unchanged from €237.0m at last update. Net income forecast to grow 1,397% next year vs 20% growth forecast for Chemicals industry in France. Consensus price target of €11.00 unchanged from last update. Share price fell 8.5% to €5.14 over the past week.
Reported Earnings • Apr 16Full year 2021 earnings: EPS misses analyst expectationsFull year 2021 results: EPS: €0.03 (down from €1.70 in FY 2020). Revenue: €226.6m (down 15% from FY 2020). Net income: €195.0k (down 98% from FY 2020). Profit margin: 0.1% (down from 3.4% in FY 2020). The decrease in margin was driven by lower revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 100%. Over the next year, revenue is forecast to grow 4.6%, compared to a 22% growth forecast for the industry in France. Over the last 3 years on average, earnings per share has increased by 60% per year but the company’s share price has only increased by 2% per year, which means it is significantly lagging earnings growth.
Major Estimate Revision • Mar 22Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 EPS estimate increased from €0.25 to €0.33. Revenue forecast unchanged at €237.0m. Net income forecast to shrink 61% next year vs 15% decline forecast for Chemicals industry in France. Consensus price target up from €10.02 to €10.50. Share price rose 6.2% to €5.84 over the past week.
분석 기사 • Mar 15Returns At Orapi (EPA:ORAP) Are On The Way UpWhat trends should we look for it we want to identify stocks that can multiply in value over the long term? In a...
Valuation Update With 7 Day Price Move • Mar 14Investor sentiment improved over the past weekAfter last week's 17% share price gain to €5.50, the stock trades at a forward P/E ratio of 43x. Average forward P/E is 13x in the Chemicals industry in France. Total loss to shareholders of 8.3% over the past three years.
Price Target Changed • Feb 02Price target decreased to €10.50Down from €12.00, the current price target is provided by 1 analyst. New target price is 80% above last closing price of €5.84. Stock is down 41% over the past year. The company is forecast to post earnings per share of €0.0079 for next year compared to €1.70 last year.
Valuation Update With 7 Day Price Move • Nov 29Investor sentiment improved over the past weekAfter last week's 17% share price gain to €7.50, the stock trades at a forward P/E ratio of 67x. Average forward P/E is 18x in the Chemicals industry in France. Total returns to shareholders of 23% over the past three years.
분석 기사 • Nov 17Orapi (EPA:ORAP) Has A Somewhat Strained Balance SheetThe external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Reported Earnings • Sep 22First half 2021 earnings released: EPS €0.37 (vs €1.92 in 1H 2020)The company reported a poor first half result with weaker earnings, revenues and profit margins. First half 2021 results: Revenue: €117.6m (down 16% from 1H 2020). Net income: €2.46m (down 72% from 1H 2020). Profit margin: 2.1% (down from 6.3% in 1H 2020). Over the last 3 years on average, earnings per share has increased by 97% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings.
Price Target Changed • Sep 21Price target increased to €12.00Up from €10.50, the current price target is provided by 1 analyst. New target price is 73% above last closing price of €6.92. Stock is up 21% over the past year.
Price Target Changed • Jul 27Price target decreased to €10.50Down from €11.60, the current price target is provided by 1 analyst. New target price is 56% above last closing price of €6.72. Stock is up 5.0% over the past year.
Major Estimate Revision • Jul 27Consensus EPS estimates fall to €0.075The consensus outlook for earnings per share (EPS) in 2021 has deteriorated. 2021 revenue forecast decreased from €240.0m to €233.0m. EPS estimate also fell from €0.096 to €0.075. Net income forecast to shrink 87% next year vs 12% growth forecast for Chemicals industry in France . Consensus price target down from €11.60 to €10.50. Share price was steady at €6.72 over the past week.
Major Estimate Revision • Jul 06Consensus forecasts updatedThe consensus outlook for 2021 has been updated. 2021 EPS estimate increased from €0.059 to €0.096. Revenue forecast unchanged at €240.0m. Net income forecast to shrink 83% next year vs 12% growth forecast for Chemicals industry in France . Consensus price target of €11.60 unchanged from last update. Share price rose 2.2% to €6.98 over the past week.
분석 기사 • Apr 25Orapi's (EPA:ORAP) Earnings Are Of Questionable QualityDespite posting some strong earnings, the market for Orapi SA's ( EPA:ORAP ) stock hasn't moved much. Our analysis...
분석 기사 • Apr 19Is Orapi (EPA:ORAP) A Risky Investment?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Reported Earnings • Apr 17Full year 2020 earnings released: EPS €1.70 (vs €0.64 loss in FY 2019)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: €267.5m (up 11% from FY 2019). Net income: €9.22m (up €12.2m from FY 2019). Profit margin: 3.4% (up from net loss in FY 2019). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 94% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings.
분석 기사 • Feb 23Does Orapi (EPA:ORAP) Have The DNA Of A Multi-Bagger?If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. One common...
Is New 90 Day High Low • Jan 26New 90-day high: €11.30The company is up 69% from its price of €6.68 on 28 October 2020. The French market is up 15% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 3.0% over the same period.
분석 기사 • Jan 19Is Orapi SA's (EPA:ORAP) ROE Of 0.8% Concerning?While some investors are already well versed in financial metrics (hat tip), this article is for those who would like...
Is New 90 Day High Low • Dec 23New 90-day high: €8.90The company is up 56% from its price of €5.70 on 24 September 2020. The French market is up 14% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is down 2.0% over the same period.
분석 기사 • Dec 15We Think Orapi (EPA:ORAP) Is Taking Some Risk With Its DebtDavid Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Is New 90 Day High Low • Oct 21New 90-day high: €8.66The company is up 3.0% from its price of €8.42 on 23 July 2020. The French market is flat over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is down 5.0% over the same period.
Major Estimate Revision • Sep 23Analysts increase EPS estimates to €0.46The 2020 consensus revenue estimate increased from €240.9m to €256.0m. The company is forecast to report a profit instead of a loss, with analysts raising their EPS forecasts from -€0.63 to €0.46 for the same period. The Chemicals industry in France is expected to see an average net income growth of 3.7% next year. The consensus price target increased from €7.00 to €8.30. Share price is up 10.0% to €5.72 over the past week.
Reported Earnings • Sep 19First half earnings releasedOver the last 12 months the company has reported total profits of €189.0k, down 94% from the prior year. Total revenue was €251.8m over the last 12 months, largely unchanged from the prior year.
Price Target Changed • Sep 19Price target raised to €8.30Up from €7.00, the current price target is provided by 1 analyst. The new target price is 32% above the current share price of €6.28. As of last close, the stock is up 26% over the past year.